Improving survival rates for adolescents and young adults with cancer.
Globally, the incidence of sarcoma in young adults is approximately 2/100,000 persons with a greater incidence in males over females by a 2:1 ratio. Previous radiation and chemotherapy exposure before the age of 20, as well as exposure to certain chemical agents, has been linked to an increased risk in the development of sarcoma in the young adult population. Young adult sarcoma patients seem to do worse then their pediatric counterparts for a variety of reasons, one being the differences in the biology of their cancers. These differences in biology need to be accounted for when establishing treatment plans in this age group in determining pediatric- versus adult-based protocols.
Source: Soliman H, Ferrari A, Thomas D. Sarcoma in the Young Adult Population: An International View. Semin Oncol. 2009; 36:227-236.
Clinical Trial Participation and Time to Treatment Among Adolescents and Young Adults With Cancer: Does Age at Diagnosis or Insurance Make a Difference?
J Clin Oncol. 2011 Sep 19;
Authors: Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH
Abstract
PURPOSEBecause adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a...
Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead.
Crit Rev Oncol Hematol. 2011 Jul 28;
Authors: Van Gaal JC, De Bont ES, Kaal SE, Versleijen-Jonkers Y, van der Graaf WT
Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that mainly affects children, but also occurs in adolescents and (young) adults (AYA). Despite dramatic survival improvements reported by international study groups in children over the past decades, the awareness of a...
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study.
J Cancer Surviv. 2011 Jan 28;
Authors: Harlan LC, Lynch CF, Keegan TH, Hamilton AS, Wu XC, Kato I, West MM, Cress RD, Schwartz SM, Smith AW, Deapen D, Stringer SM, Potosky AL,
INTRODUCTION: Cancer is rare in adolescents and young adults (AYA), but these patients have seen little improvement in survival in contrast to most other age groups. Furthermore, participation in research by AYAs is typically low. We...
Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
J Chemother. 2009 Apr;21(2):205-10
Authors: Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, Balladelli A, Pratelli L, Bacci G
The influence of age and sex on chemotherapy-related toxicity was evaluated in children and adults with non metastatic osteosarcoma. treatment consisted of methotrexate (MTX, 12 g/m(2)), cisplatin (CDP 120 mg/m(2)) and doxorubicin (ADM 75-90 mg/m(2)) and high-dose...
Current issues in adolescent and young adult cancer survivorship.
Cancer Control. 2008 Jan;15(1):55-62
Authors: Soliman H, Agresta SV
Overall, the survival rate for cancer patients has continued to improve over the past several decades. However, those aged 15 to 29 years have not experienced the same improvements in survival. This review explores some of the challenges faced by adolescent and young adult (AYA) cancer patients and their survivorship needs.
PMID: 18094661 [PubMed -...
Adolescent and young adult (AYA) oncology: the first A.
Pediatr Hematol Oncol. 2007 Jul-Aug;24(5):325-36
Authors: Bleyer A
Whereas adolescents with cancer as a group used to have a better prognosis than children with malignant disease, trends suggest that the overall survival of 15- to 19-year-olds is now worse than in younger patients. Also, the incidence of cancer is higher in 15- to 19-year age span than during the first 15 years of life. In 2006, the U.S. National Cancer Institute (NCI) and the...
Overview of sarcomas in the adolescent and young adult population.
J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8
Authors: Herzog CE
Based on the data of the Surveillance, Epidemiology and End Results Section of the National Cancer Institute (SEER) program, soft tissue and bone sarcomas account for about 1% of all new malignancies diagnosed in the United States each year. However, there are numerous different histologic types, and any given type of sarcoma is extremely rare. Determining the...
[Chromosome and DNA analyses of peripheral blood lymphocyte from the quadruple cancer patient].
Gan To Kagaku Ryoho. 1992 Jul;19(7):1055-7
Authors: Yamaguchi H, Kaneda K, Aya T, Imai S, Yamawaki S, Moriuchi T
The patient with quadruple cancer was a 32 year-old female who had osteosarcoma, bilateral breast cancer and adenocarcinoma of the lung. When chromosomal analysis of peripheral blood lymphocyte was performed, two abnormal cells were detected among 42 cells examined. The first cell showed a...
Sodium butyrate (SB) augments the effects of 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) on neoplastic and osteoblastic phenotype in clonal rat osteosarcoma cells.
Biochem Biophys Res Commun. 1984 Jun 29;121(3):796-801
Authors: Yoneda T, Aya S, Sakuda M
1,25 Dihydroxyvitamin D3 suppressed colony formation in soft agar and increased alkaline phosphatase activity in clonal rat osteosarcoma cells. Sodium butyrate enhanced these effects of the hormone partly through a mechanism involving an alteration of...
from patients, caregivers and medical professionals dealing with this disease and many other diseases
Share This Tip